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SUMMARY
Mutations in the microtubule-associated protein tau (MAPT) gene are known to cause familial frontotemporal dementia (FTD). The
R406W tau mutation is a unique missense mutation whose patients have been reported to exhibit Alzheimer’s disease (AD)-like phenotypes rather than the more typical FTD phenotypes. In this study, we established patient-derived induced pluripotent stem cell (iPSC)
models to investigate the disease pathology induced by the R406W mutation. We generated iPSCs from patients and established isogenic
lines using CRISPR/Cas9. The iPSCs were induced into cerebral organoids, which were dissociated into cortical neurons with high purity.
In this neuronal culture, the mutant tau protein exhibited reduced phosphorylation levels and was increasingly fragmented by calpain.
Furthermore, the mutant tau protein was mislocalized and the axons of the patient-derived neurons displayed morphological and
functional abnormalities, which were rescued by microtubule stabilization. The findings of our study provide mechanistic insight
into tau pathology and a potential for therapeutic intervention.

INTRODUCTION
Frontotemporal dementia (FTD) is one of the most common types of early-onset dementia after Alzheimer’s disease (AD). In some familial cases, it is caused by mutations
in the microtubule-associated protein tau (MAPT) gene,
which encodes the tau protein (Hutton et al., 1998; Poorkaj
et al., 1998; Spillantini et al., 1998). Over 50 mutations on
the MAPT gene have been reported to cause FTD (Ghetti
et al., 2015), and the patients exhibit diverse clinical phenotypes (Ghetti et al., 2011). The R406W missense mutation is one such pathological mutation located on exon
13 of the MAPT gene (Hutton et al., 1998; Rizzu et al.,
1999; Van Swieten et al., 1999). Interestingly, patients
with this mutation have been reported to exhibit AD-like
phenotypes: early memory impairment is a primary presenting feature, while the more typical FTD symptoms,
including changes in social behavior and personality, as
well as motor symptoms (Foster et al., 1997), are less predominant or not seen at all (Ikeuchi et al., 2011).
As of today, there is no effective treatment for FTD
patients. It is crucial to gain a better understanding of
the disease pathogenesis for the development of novel

therapeutic strategies. Previous studies using transgenic
murine models and postmortem patient brains have
yielded significant insights into the disease mechanism,
but each have their own shortcomings. The former
model has not been able to completely recapitulate
human disease pathology, possibly due to species differences and overexpression of the tau transgene in irrelevant brain areas (Denk and Wade-Martins, 2009), and
the latter cannot model disease onset or progression,
and cannot be easily accessed for research purposes due
to ethical limitations. Thus, there is a need for a model
that is readily accessible and can accurately recapitulate
the disease pathogenesis. Recently, considerable attention has been given to the potential of human induced
pluripotent stem cell (iPSC) technology (Takahashi
et al., 2007) for disease modeling. Human iPSCs have
the potential to differentiate into neurons, which have
previously been difficult to obtain. Using this model
could thereby provide us with a deeper understanding
of the molecular mechanism of the disease onset and
progression.
Previously there have been reports on the generation of
MAPT R406W iPSC lines, but those conducting phenotype
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analysis at the molecular level have been limited (Jiang
et al., 2018; Nimsanor et al., 2016a, 2016b; Rasmussen
et al., 2016a, 2016b). On the one hand, Imamura et al.
(2016) has observed an accumulation of misfolded tau,
calcium dysregulation, and neuronal cell death in FTD
iPSC models, including those carrying the R406W mutation, but as these phenotypes were commonly found in
neurons with other tau mutations as well, the pathological
mechanism specific for the R406W mutation remains
unexplored.
Here, we sought to establish a model that can recapture
the disease pathogenesis induced by the R406W mutation,
as a basis for therapeutic development for tauopathies
including FTD and AD. Using neurons differentiated from
patient-derived iPSCs and their corresponding isogenic
lines, we identified the biochemical changes of tau induced
by the R406W mutation and their effects at the cellular
level.

RESULTS
Generation and Characterization of the MAPT R406W
iPSCs
MAPT R406W iPSCs were established from two Japanese
FTD patients (patients #1 and #2) of the same pedigree,
whose primary symptom was memory impairment (Ikeuchi et al., 2011; Table S1). DNA sequencing confirmed
that the patients were heterozygous for the mutation
(MAPTR406W/+, Figure 1D; Ikeuchi et al., 2011). The
patients had no other mutations besides the MAPT
R406W mutation, as previously confirmed (Ikeuchi
et al., 2011).
The iPSCs were generated by using the integration-free
episomal vector system, as described previously (Ichiyanagi
et al., 2016; Nakamoto et al., 2018; Okita et al., 2013). PCR
analysis confirmed the removal of the episomal vectors
from several clones (Figure S1A). These clones stained positively for the pluripotency markers alkaline phosphatase
(Figure 1A) and TRA-1-60 (Figure 1B) and were karyotypically normal (Figure S1B).
We utilized another MAPT R406W iPSC line generated
with Sendai virus vectors from a symptomatic subject of
an unrelated pedigree (patient #3), who was also heterozy-

gous for the mutation (Jiang et al., 2018; Table S1). The
201B7 iPSC line, derived from a healthy subject, was
obtained for use as a control for subsequent experiments
(Takahashi et al., 2007).
Generation of Isogenic iPSC Lines with CRISPR/Cas9
Next, we utilized CRISPR/Cas9 technology to manipulate
the mutation site for the generation of isogenic lines
(Cong et al., 2013) in order to reduce the variability of
experiments caused by genetic heterogeneity. Targeting
vectors were designed to include the mutation site on
the 30 arm and a selection cassette in between the two
arms, with PiggyBac inverted terminal repeats at both
ends to enable footprint-free excision (Figure 1C). Transfection experiments were performed, and colonies that
survived drug selection were picked up and analyzed.
Consequently, DNA sequencing revealed the successful
manipulation of the mutation site, confirming the
generation of isogenic wild-type (WT) MAPT+/+ lines and
homozygous mutant (MAPTR406W/R406W) lines (Figure 1D).
Finally, the gene-edited clones were transfected with the
PiggyBac transposase for the excision of the selection
cassette (Nakamoto et al., 2018). DNA-sequencing analysis
in the manipulated region confirmed that these isogenic
clones were free of genomic indels and other unintended
mutations (Figure S1C).
Establishment of iPSC-Derived Neuron-Rich Culture
via Dissociation of Cerebral Organoids
The iPSC lines were then subjected to neuronal differentiation for subsequent analysis (Figure 2A). We utilized the
method for inducing cerebral organoids (Kadoshima
et al., 2013; Lancaster et al., 2013), since previous reports
have implicated that three-dimensional (3D) cultures
may accelerate disease pathology compared with conventional two-dimensional (2D) cultures (Choi et al., 2014).
However, because cerebral organoids consist of a heterogeneous population of cells (Quadrato et al., 2017) and the
cells within the organoids are densely packed, we found
that the use of cerebral organoids as a whole was not suitable for biochemical analyses and morphological observations of neurons. Thus, we devised a method to isolate a
pure population of cortical neurons from the organoids.

Figure 1. Generation and Characterization of iPSCs from FTD MAPT R406W Patients
(A and B) Immunofluorescence for pluripotency markers alkaline phosphatase (A) and TRA-1-60 (B). Representative clones from each
patient are shown. Scale bars, 500 mm.
(C) Schematic diagram of the construction of targeting vectors. Top: construct of the WT targeting vector for the generation of WT lines.
Bottom: construct of the mutant targeting vector for the generation of homozygous mutant lines.
(D) DNA sequence of the mutation site in the heterozygous patient line (MAPTR406W/+) and in the gene-edited isogenic lines (WT line:
MAPT+/+, homozygous mutant line: MAPTR406W/R406W).
See also Figure S1.
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After 30 days of culture, we dissociated the organoids onto
typical 2D culture dishes and cultured them for an additional 30 days, at which point these cultures were
evaluated by immunofluorescence. Lines that were successfully induced into organoids and dissociated consisted of
neurons positive for MAP2, TBR1, and tau (Figure 2B).
Quantification revealed that all the lines evaluated were
>85% positive for neuronal markers MAP2 and bIII-tubulin
(Figures 2C and 2D), and also highly positive for forebrain
(cortical neuron) markers TBR1 and FOXG1, as well as
NeuN, indicating the presence of mature neurons (Figures
2E–2G), with similar differentiation efficiency among
lines. The yield of live cells from one dissociated organoid
of any given line was approximately 4 3 105 cells (equivalent to the number of cells plated onto one well of a 12-well
plate), the majority of which we assumed to be neurons
(Figure 2H).
Unfortunately, because all the iPSC lines derived
from patient #1 did not efficiently differentiate into neurons with our protocol, we focused on using iPSC-derived
neurons from patients #2 and #3 for the subsequent
analyses.
R406W Mutant Tau Is Less Phosphorylated by Multiple
Kinases
Tau hyperphosphorylation is a key hallmark of tauopathies (Spillantini and Goedert, 2013). Interestingly, western blot analysis revealed that tau phosphorylation at
S409 and T181 were lowered in both MAPTR406W/+ and
MAPTR406W/R406W neurons compared with the control
neurons 30 days after dissociation (Figures 3A–3D, S2A,
and S2B). The phosphorylation level of S404 also
appeared to decrease when analyzed with an S404
phosphorylation-dependent tau antibody (Figures S2C
and S2D), as previously reported (Sakaue et al., 2005).
However, reduced phosphorylation was not observed
with the PHF1 antibody, which recognizes both S396
and S404 (data not shown), suggesting that the reduction
seen with the S404 phosphorylation-specific antibody
may simply be reflecting a change in immunogenicity
due to the mutation. Tau phosphorylation levels were
already reduced even at an earlier time point of 10 days

post dissociation (Figures S5A–S5C). Furthermore, coexpression of the glutathione S-transferase-conjugated
C-terminal fragment of WT or R406W tau with various
kinases in vitro revealed that the mutation impaired the
phosphorylation of S404 by GSK3b and CDK5 and the
phosphorylation of S409 by Rho-associated protein
kinase (RhoK) and protein kinase A (PKA) (Figure S3A).
These findings support the results obtained with the
iPSC-derived neurons and suggest that the R406W mutation potentially impairs the phosphorylation of tau by
multiple kinases.
In addition, when blotting with pan-tau antibody
Tau5, we found that the samples exhibited two major
bands (48 kDa and 55 kDa). The intensity of the 48kDa band was increased in the mutant samples derived
from patients #2 and #3 at both 10 days and 30 days after
dissociation (Figures 3E, 3F, S2E, S2F, S5D, and S5E). The
two bands differed in the phosphorylation level of tau,
with the 48-kDa band representing the less phosphorylated form of tau (hereafter termed ‘‘hypophosphorylated’’ tau), since both bands shifted downward and
merged into one band representing the 0N3R tau isoform
when the samples were treated with l-phosphatase for
dephosphorylation (Figure S2G). Furthermore, the
amount of 48-kDa tau increased with GSK3b inhibition
using SB216763, which implicates GSK3b as the kinase
most responsible for the reduced phosphorylation levels
of R406W mutant tau (Figures 3G and 3H). In support
of our finding, treatment with CHIR99021, a more specific GSK3b inhibitor, resulted in a dose-dependent increase of the 48-kDa band (Figures S3B and S3C). This
is consistent with the results obtained when co-expressing tau and various kinases in COS-7 cells, showing
that S404 and S409 are also potential phosphorylation
sites of GSK3b and that their phosphorylation by
GSK3b is impaired in the R406W mutation (Figures
S3D–S3F). Importantly, the phosphorylation level of
b-catenin, another major GSK3b substrate, remained unchanged, implying that the reduced tau phosphorylation
was not due to a change in GSK3b activity but rather a
change in accessibility to the tau protein because of the
mutation (Figures S3G and S3H).

Figure 2. Neural Differentiation of R406W iPSCs via Cerebral Organoid Dissociation
(A) Schematic timeline for neuronal differentiation of iPSCs using the protocol for cerebral organoid induction. Organoids were dissociated
into cortical neurons and cultured on typical two-dimensional plates. All analyses were performed after 60 days of culture. Scale bar,
500 mm (day 9, day 30), 50 mm (day 60).
(B) Immunofluorescence of iPSC-derived cortical neurons using neuronal markers MAP2 and bIII-tubulin, forebrain marker TBR1, tau, and
DAPI for nuclear staining. Scale bars, 50 mm.
(C–G) Quantification of the percentage of cells expressing pan-neuronal markers MAP2 (C), bIII-tubulin (D), and NeuN (G), and forebrain
markers TBR1 (E) and FOXG1 (F) in each iPSC-derived neuronal line (n = 3 independent experiments).
(H) Quantification of the number of live cells obtained from one dissociated organoid (n = 3 independent experiments).
Error bars indicate mean ± SEM.
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Figure 3. Reduction of Phosphorylation in R406W Mutant Tau by Multiple Kinases
(A–D) Western blot analysis investigating tau phosphorylation levels at S409 (A) or T181 (C). Both pS409 and pT181 levels were
significantly reduced in the R406W mutant samples (S409, B; T181, D) relative to total tau levels (K9JA) (n = 2–3 independent
experiments).
(E and F) Western blot analysis with pan-tau antibody Tau5 (E) revealed an increase in the ratio of 48-kDa tau (arrowhead) to total tau
(both 48-kDa and 55-kDa bands) in the R406W mutant sample (F) (n = 3–4 independent experiments).
(legend continued on next page)
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The phosphorylation state of tau is known to be regulated by a balance between kinases and phosphatases. To
determine whether changes in phosphate activity were
involved in the decrease in tau phosphorylation, we
measured PP2A activity in our cells, but did not find differences among the control and mutant samples (Figure S3I).
Collectively, our analyses suggest that the R406W
mutant tau was less phosphorylated by multiple kinases,
with poor phosphorylation by GSK3b particularly accounting for the overall reduction of phosphorylation.
Increased Fragmentation of R406W Tau by Calpain
Tau is reportedly cleaved by several proteases to produce
tau fragments of different lengths (Chesser et al., 2013).
Western blot analysis revealed an increase in tau fragments
ranging from 35 to 45 kDa in the R406W mutant samples
across various epitopes (Figures 4A, 4B, and S4A–S4D).
This was especially evident when blotting with Tau12,
which recognizes the N terminus of tau, implying that
the mutation particularly increases the generation of N-terminal tau fragments (Figures 4A and 4B). Next, we attempted to identify the protease generating these fragments.
Neurons were treated either with a pan-caspase inhibitor
(Z-FAD-VMK) or pan-calpain inhibitor (ALLN). Western
blot analysis revealed a decrease of the 35-kDa fragment
in samples treated with the calpain inhibitor, but not the
caspase inhibitor (Figures 4C and 4D), indicating that calpain was generating the specific fragment. Interestingly,
blotting with Tau5 revealed that the amount of hypophosphorylated tau (48 kDa) increased with calpain inhibition
(Figures 4E and 4F). We presumed that the hypophosphorylated tau was mainly fragmented by calpain and
that the reduction of phosphorylation caused by the
R406W mutation made the mutant tau more susceptible
to calpain cleavage.
R406W Mutation Induces Tau Mislocalization and
Axonal Dystrophy by Microtubule Destabilization
Dissociated neurons were further examined for phenotypes
at the cellular level. Immunofluorescence of the neurons
with tau and MAP2 revealed an increased colocalization
of the two markers in the mutant neurons (Figure 5A).
Quantitative analysis confirmed that the mutant neurons
had a small but significant increase of tau on MAP2-positive dendrites at 30 days after dissociation (Figure 5B).
These results suggest that the R406W mutant tau is more

likely to mislocalize from the axons to the dendrites of
the neurons.
The morphology of the neurons was also investigated
with immunofluorescence. Immunostaining with bIIItubulin revealed a considerable number of dystrophic
neurites in the mutant neurons (Figure 5C). Such a staining
pattern was not observed with MAP2, indicating that
the axons, but not the dendrites, were undergoing
degeneration. At 30 days post dissociation, the axons of
the mutant neurons consisted of a significantly greater
number of small puncta (Figures 5D and 5E). Tau mislocalization and axonal dystrophy were not observed at an
earlier time point of 10 days post dissociation (Figures S5F
and S5G).
Interestingly, there were fewer axonal puncta when the
mutant neurons were treated with Epothilone D (EpoD),
a microtubule (MT) stabilizer (Figures 5D and 5E). Altogether, these results suggest that the R406W mutant tau
may cause axonal degeneration by altering MT dynamics
and/or stability.
MT Destabilization Disrupts Mitochondrial Transport
in the Mutant Neurons
Because axonal degeneration occurred in the mutant neurons, we presumed that the function of the axons in these
neurons may be disrupted as well. Axonal transport is one
such process responsible for carrying organelles and
proteins within neurons. Transport of mitochondria is
particularly important, because neurons have high energy
demands and require a large supply of ATP to maintain
their function and survival (Schwarz, 2013). As such, mitochondrial dysfunction has been implicated during the
early stages of multiple neurodegenerative diseases (Lin
and Beal, 2006). Thus, we decided to investigate whether
there were any defects in mitochondrial transport. After
transfecting neurons with Mito-eYFP and tdTomato, we
performed live-imaging analysis of the mitochondria in
intact axons. We found mitochondria in the mutant
neurons to be less stationary and moving more in the retrograde direction (Figure 6A). In support of our finding, fewer
mitochondria were in the axons of the mutant neurons
compared with those in the WT neurons, which again
was rescued with EpoD treatment (Figures 6B and 6C).
Overall, these results suggest that the R406W tau-induced
MT destabilization caused impairment of the axonal transport machinery.

(G and H) Western blot analysis investigating the effects of kinase inhibitors SB216763, KT5720, Y27632, and Roscovitine (inhibitors of
GSK3b, PKA, RhoK, and CDK5, respectively) on the phosphorylation pattern of tau in WT (201B7) iPSC-derived neurons (G). Quantification
of the ratio of 48-kDa tau to total tau (both 48-kDa and 55-kDa bands) revealed an increase of the ratio with SB216763 treatment, a GSK3b
inhibitor, in comparison with that with the mock treatment of DMSO (H) (n = 3 independent experiments).
Error bars indicate mean ± SEM. One-way ANOVA followed by Tukey’s test was performed. *p < 0.05, **p < 0.01, ***p < 0.001. See also
Figures S2, S3, and S5.
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Figure 4. Increased Cleavage of Tau by Calpain Is Dependent on the Phosphorylation State
(A and B) Western blot analysis with pan-tau antibody Tau12 (A) revealed increased tau fragments ranging from 35 to 45 kDa (bracket)
relative to full-length (FL) tau (brace) in the R406W mutant samples (B) (n = 3 independent experiments).
(C and D) Western blot analysis of MAPTR406W/R406W samples with Tau12 when treated with 120 mM Z-VAD-FMK (pan-caspase inhibitor),
250 mM ALLN (pan-calpain inhibitor), or DMSO (mock) (C) revealed a decreased ratio of 35-kDa tau fragments (arrow) to full-length (FL) tau
(brace) with calpain inhibition (D) (n = 3 independent experiments).
(E and F) Western blot analysis of MAPTR406W/R406W samples with Tau5 when treated with 120 mM Z-VAD-FMK (pan-caspase inhibitor),
250 mM ALLN (pan-calpain inhibitor), or DMSO (mock) (E) revealed an increased ratio of hypophosphorylated tau (48 kDa; arrowhead) to
total tau (both 48-kDa and 55-kDa bands) with calpain inhibition (F) (n = 3 independent experiments).
Error bars indicate mean ± SEM. One-way ANOVA followed by Tukey’s test was performed. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001. See also Figure S4.
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DISCUSSION
The role of tau in neurodegeneration has been extensively
studied using various models. Development of tau transgenic animal models and cell-line models has provided
fundamental insight of tau under both physiological and
pathological conditions (Denk and Wade-Martins, 2009;
Lim et al., 2014). In the case of R406W mutant tau, hyperphosphorylation and aggregation of tau into filament-like
structures (Ikeda et al., 2005; Tatebayashi et al., 2002), as
well as retardation of axonal transport (Zhang et al.,
2004), has been reported in R406W tau transgenic mice.
In cell-line models, soluble R406W tau was less phosphorylated and its binding to microtubules was reduced (Tatebayashi et al., 2006; Matsumura et al., 1999; Dayanandan
et al., 1999; Perez et al., 2000; Krishnamurthy and Johnson,
2004). However, the number of studies using a human
model has been limited (Imamura et al., 2016; Jiang et al.,
2018) and the pathological progression has not been
entirely elucidated. Therefore, in this study we developed
a patient-derived neuronal model using iPSC technology
to recapture the disease pathology induced by the MAPT
R406W mutation.
Taking advantage of the CRISPR/Cas9 gene-editing technology and the PiggyBac transposase system (Cong et al.,
2013; Yusa et al., 2011), we established footprint-free
isogenic WT (MAPT+/+) or homozygous (MAPTR406W/R406W)
iPSC lines from the original heterozygous R406W
(MAPTR406W/+) patient-derived iPSC lines. These lines have
a genetically identical background, making them important
tools for assessing the genotype-phenotype relationship.
Using previously reported protocols, we generated cerebral organoids from our iPSC lines (Kadoshima et al.,
2013; Lancaster et al., 2013). Building on this approach,
we developed a method to isolate a homogeneous population of cortical neurons from the organoids. With our
protocol, we were able to obtain a high percentage of cells
expressing pan-neuronal markers (>85%–90%) and forebrain markers (80%) without the use of transgenes (Zhang
et al., 2013). There was also a high expression of NeuN, indicating the presence of mature neurons. Furthermore, we
can obtain a great number of neurons by dissociating a
bulk of organoids, and it is possible to regulate this number
by manipulating the number of organoids to be dissociated,
making this method feasible for various types of analyses.
To our knowledge, this is the first time dissociated organoids
were used for disease modeling, and we clearly showed that
the dissociated culture is suitable for both biochemical and
immunochemical analyses. Hence, we demonstrated the
utility of organoids for applications besides 3D modeling.
Using our neuronal culture, we first examined the phosphorylation state of the mutant tau. Abnormal phosphorylation of tau is a pathological hallmark of AD and other
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tauopathies, which is known to trigger tau pathology by
reducing its affinity to microtubules, enhancing aggregation, altering its interactions with other proteins, and
missorting it from axons to the somatodendritic compartments in neurons (Wang and Mandelkow, 2016). Several
studies have reported the aberrant phosphorylation status
of R406W mutant tau, but results have been controversial.
Results from in vitro experiments and non-neuronal cell
lines indicated R406W mutant tau to be less phosphorylated than WT tau (Dayanandan et al., 1999; Matsumura
et al., 1999; Perez et al., 2000; Sakaue et al., 2005; Tatebayashi et al., 2006), while studies using murine models or
postmortem R406W patient brains claimed that they
were hyperphosphorylated (Ikeda et al., 2005; Krishnamurthy and Johnson, 2004; Miyasaka et al., 2001; Tatebayashi
et al., 2002). These controversies may have arisen because
of the differences in tau solubility and the disease stages
reflected in each model. In our human iPSC-derived
neuronal model, R406W mutant tau was found to be less
phosphorylated at specific epitopes. In addition to demonstrating reduced phosphorylation at T181 and S404, we
newly identified S409 to be less phosphorylated in the
mutant tau using western blot analyses. Using in vitro
experiments, we further went on to reveal that the mutation impaired phosphorylation by PKA, RhoK, and
GSK3b at these epitopes. In particular, GSK3b accounted
for the overall reduction of phosphorylation, which is
supported by the fact that T181, S404, and S409 are all potential phosphorylation sites by this kinase (Reynolds et al.,
2000). However, it should be noted that the reduction of
phosphorylation at S404 is debatable when taking into
consideration a change in immunogenicity due to the mutation. Nevertheless, based on our findings and those from
previous reports, it is highly plausible that the arginine-totryptophan substitution makes tau less prone to phosphorylation by specific kinases, possibly due to some conformational change of the mutant tau. However, as the disease
progresses, the mutant tau may become hyperphosphorylated, due to a mechanism not yet identified, as seen in
the murine models and patients’ brains (Ikeda et al.,
2005; Krishnamurthy and Johnson, 2004; Miyasaka et al.,
2001; Tatebayashi et al., 2002).
Results regarding the efficiency of R406W mutant tau to
bind and/or assemble microtubules compared with WT tau
have also been controversial (DeTure et al., 2000; Hong
et al., 1998; Dayanandan et al., 1999; Perez et al., 2000;
Hasegawa et al., 1998; Krishnamurthy and Johnson,
2004). Here, we demonstrated that the mutant tau induces
cellular phenotypes through the destabilization of microtubules. These phenotypes were rescued by treatment
with the microtubule stabilizer EpoD, suggesting that the
R406W mutation exerts negative effects on the physiological interaction of tau with microtubules.
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Investigation at the cellular level revealed the mislocalization of tau to the dendrites and more punctuate axons
in the mutant neurons, both of which have been observed
in AD brains (Kowall and Kosik, 1987). Furthermore, there
was a decrease in the number of mitochondria on the axons
of the mutant neurons. Impairment of mitochondrial distribution has also been reported in an rTg4510 mouse
model and in AD patient brains (Kopeikina et al., 2011),
as well as in a P301L tau knockin mouse model, which
has also interestingly found elevated amounts of hypophosphorylated tau (Rodrı́guez-Martı́n et al., 2016). In
addition, live-imaging analysis showed that mitochondria
in the mutant neurons were less stationary, and an
increased percentage moved more in the retrograde direction away from the axons, which is consistent with the
reduction of its number in the axons. This is in contrast
to a previous study also using FTD patient-derived iPSC
neurons, which reported that mitochondria in the mutant
neurons were less mobile (Iovino et al., 2015). This discrepancy may be due to the differences in the mutations
analyzed (R406W in this study versus P301L and N279K
in Iovino et al., 2015). A previous report has demonstrated
that microtubule-bound tau inhibits the motility of kinesin
and dynein, and that the microtubule binding domain
(MTBD) of tau is sufficient for this inhibition (Dixit et al.,
2008). Thus, the impaired association of R406W tau with
MTs may have promoted dynein to become overly motile,
resulting in the increase in retrograde movement of mitochondria. In support of this, the axonal mitochondrial
number in the mutant neurons was rescued with EpoD
treatment, confirming that MT destabilization induced by
the mutant tau caused the transport defect.
Despite the numerous reports on tau pathology, the
pathological cascade leading to neurodegeneration is still
unknown. For example, the specific role of aberrant tau
phosphorylation during pathological progression remains
widely unexplored. In this study, we found that reduced
tau phosphorylation makes tau more susceptible to calpain
cleavage to generate 35-kDa N-terminal fragments. The
calpain cleavage site of tau has been reported to be near
or inside the MTBD (Chen et al., 2018; Garg et al., 2011).

Therefore, the resultant tau fragment either may have
lost its ability to stabilize microtubules or have gained a
toxic function to destabilize them, ultimately triggering
the axonal phenotypes. Furthermore, although the cellular
phenotypes could be observed in the mutant neurons at
30 days after dissociation, they could not be detected
at an earlier time point. However, tau hypophosphorylation already occurred at 10 days post dissociation. Thus,
abnormal tau phosphorylation seen in this study could
be an early hallmark of the disease that triggers the consequent pathological events, such as MT destabilization,
axonal dystrophy, and axonal transport defects.
Our study reports a previously unidentified molecular
mechanism of tau pathology specifically induced by
the R406W mutation. Understanding the cascade of
pathological events leading to neurodegeneration using
iPSC-derived models will help in defining targets for therapeutic development for a wide variety of tauopathies and
other neurodegenerative diseases.

EXPERIMENTAL PROCEDURES
All experimental procedures for iPSCs derived from patients were
approved by the Keio University School of Medicine Ethics Committee (approval no. 20080016).

Cell Culture
Peripheral blood cells from two patients with the MAPT R406W
mutation were obtained (Ikeuchi et al., 2011), which were maintained in T cell medium, consisting of KBM502 medium (Kohjin
Bio, Saitama, Japan) supplemented with Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher Scientific, Waltham, MA, USA).
iPSCs were maintained on irradiated mouse embryonic fibroblasts or SNL 76/7 feeder cells in iPSC medium, consisting of
DMEM/F12 medium (Wako, Osaka, Japan) supplemented with
0.08 mM MEM-Non Essential Amino Acid solution (Sigma-Aldrich,
St. Louis, MO, USA), 2 mM L-glutamine, 20% (v/v) Knockout
Serum Replacement (Thermo Fisher Scientific), 80 U/mL penicillin,
80 mg/mL streptomycin, 0.1 mM 2-mercaptoethanol, and 10 ng/mL
basic fibroblast growth factor (PeproTech, Rocky Hill, NJ, USA).
Feeder-free iPSCs were maintained on culture dishes coated with
0.25–0.5 mg/mL iMatrix-511 (Laminin-511E8) (Wako) in StemFit

Figure 5. Axonal Phenotypes Caused by MT Destabilization in R406W Mutant Neurons
(A and B) Immunostaining of iPSC-derived neurons with MAP2, tau, and DAPI 30 days after dissociation (A). Arrowheads indicate neurons
with tau on MAP2+ area. Scale bars, 10 mm. The percentage of tau on the dendrites was significantly increased in the mutant neurons when
compared with the control neurons (B) (n = 3 independent experiments, *p < 0.05; one-way ANOVA followed by Tukey’s test).
(C) Immunostaining of iPSC-derived neurons with MAP2, bIII-tubulin, and tau. Scale bars, 20 mm.
(D and E) Representative immunofluorescence pictures of bIII-tubulin+ axons with (lower) or without (upper) Epothilone D (EpoD)
treatment (D). Scale bars, 10 mm. There was a significantly greater number of puncta in the mutant neurons compared with control
neurons, which was rescued with EpoD treatment (E) (n = 3 independent experiments). ***p < 0.001, ****p < 0.0001 when comparing
control with R406W mutants; one-way ANOVA followed by Tukey’s test. #p < 0.05, ###p < 0.001 when comparing mock with EpoD; Student’s
t test.
Error bars indicate mean ± SEM. See also Figure S5.
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Figure 6. Mitochondrial Transport Defects in R406W Mutant Neurons
(A) Quantification of live-imaging mitochondrial trafficking revealed mitochondria in the mutant neurons (patient #2) to be less
stationary and moving more in the retrograde direction, when compared with those in the control neurons (n = 3 independent
experiments; *p < 0.05, **p < 0.01, two-way ANOVA followed by Tukey’s test).
(B and C) Representative pictures of fluorescent signals from iPSC-derived neurons transfected with Mito-eYFP and tdTomato, and
immunostained with DAPI (C). Scale bars, 10 mm. There were fewer mitochondria on the axons of R406W mutant neurons compared with
control neurons (B) (n = 3 independent experiments; **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA followed by Tukey’s test),
which recovered to the control level with EpoD treatment (n = 3 independent experiments; #p < 0.05, ##p < 0.01, ###p < 0.001, Student’s
t test).
Error bars indicate mean ± SEM.

AK02N medium (Ajinomoto, Tokyo, Japan). Medium was changed
every day for iPSCs on feeder and every other day for feeder-free
iPSCs.

Generation and Dissociation of Cerebral Organoids
Organoids were generated from the iPSCs as previously described
with slight modifications (Figure 2A; Lancaster et al., 2013;
Kadoshima et al., 2013; described in Supplemental Experimental
Procedures). Day-30 organoids were dissociated into single cells using the Nerve Cell Dissociation Medium A (KAC, Kyoto, Japan).
5 3 104 cells, 1 3 105 cells, and 5 3 105 cells were plated onto
60 mg/mL poly-L-ornithine (Sigma-Aldrich) and 10 mg/mL laminin

(R&D Systems, Minneapolis, MN, USA)-coated 96-well, 48-well,
and 12-well cell-culture plates, respectively (Greiner Bio-One,
Kremsmünster, Austria) and cultured for another additional
30 days in Neurobasal medium supplemented with 1% (v/v) B27
supplement with vitamin A, 0.25% (v/v) Glutamax, and 1% (v/v)
penicillin/streptomycin.

Immunofluorescence
The cells were fixed in 4% (w/v) paraformaldehyde for 15–20 min
at room temperature, followed by washing in PBS three times for
5 min each. After permeabilization with 0.2% (v/v) Triton X-100
for 15–20 min, the cells were again washed in PBS three times for
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5 min each. Samples were incubated in StartingBlock (TBS) Blocking Buffer (Thermo Fisher Scientific) for 1 h at room temperature.
Incubation with primary antibodies was performed overnight at
4 C. The following day, the cells were incubated with secondary
antibodies for 1 h at room temperature. The cells were observed
with a Zeiss LSM700 confocal microscope. Quantification of the
immunofluorescence was performed with an In Cell Analyzer
6000 (GE Healthcare, Little Chalfont, UK).

Western Blot
Cells were dissociated from the culture plates and dissolved in lysis
buffer containing 20 mM HEPES, 1 mM MgCl2, 100 mM NaCl,
0.5% NP-40, 1 mM dithiothreitol, 0.4 mM Pefabloc (4-(2-aminoethyl)-benzene-sulfonyl fluoride), 10 mg/mL leupeptin, 10 mM
NaF, and 10 mM b-glycerophosphate. After homogenization and
sonication, the samples were centrifuged at 15,000 3 g for
15 min at 4 C. For dephosphorylation, samples were treated
with 20 U Lambda Protein Phosphatase (New England Biolabs, Ipswich, MA, USA) for 3 h at 30 C. The protein samples were diluted
in 43 Laemmli Buffer (BioRad, Hercules, CA, USA) with 10 mM
2-mercaptoethanol and boiled at 95 C for 5 min. The lysates and
the Tau Protein Ladder (rPeptide, Athens, GA, USA) were loaded
onto Extra PAGE One Precast Gels 7.5%–12.5% (Nacalai Tesque,
Kyoto, Japan). SDS-PAGE was performed at 120 V for 105 min.
The proteins separated in the gel were transferred onto an Immobilon-P membrane (EMD Millipore). The membranes were blocked
with 5% (w/v) skim milk for 30 min and incubated with antibodies
diluted in Can Get Signal Immunoreaction Enhancer Solutions
(Toyobo, Osaka, Japan). Signals on the membranes were visualized
with the ECL Prime detection kit (GE Healthcare) and the images
were acquired on an ImageQuant LAS 4000 (GE Healthcare).
For quantification, we normalized the levels of phosphorylated
tau and tau fragments to total tau and full-length tau, respectively
(see corresponding figure legends for further details). We have not
included the quantification of total tau levels in our study because
normalization with the highly variable GAPDH levels among
different neuronal lines confounded our results.

Tau Localization Assay
The localization of tau was analyzed with an In Cell Analyzer 6000
(GE Healthcare). Dissociated neurons were immunostained with
MAP2, bIII-tubulin, and tau, and the percentage of tau on MAP2and bIII-tubulin-positive regions was quantified. Dendritic and
axonal tau was defined as tau on MAP2-positive area and tau on
bIII-tubulin-positive but MAP2-negative area, respectively.

Neurite Puncta Count
Confocal images of the neurites were obtained with the Zeiss
LSM700 oil immersion 1003 objective. The number of puncta
on neurites was counted manually. For normalization, the length
of the neurites was measured using the Fiji plugin Simple Neurite
Tracer. Cultures were treated with or without 20 nM EpoD (Abcam)
for 24 h for the rescue experiment.

Mitochondria Count
To visualize mitochondria, we transfected the dissociated neurons
with pcDNA3 Mito-eYFP (kindly provided by Drs. T. Tomiyama
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and T. Umeda, Osaka City University) and tdTomato expression
vectors. Confocal images of the mitochondria on the axons were
taken with a Zeiss LSM700 oil immersion 633 objective. The
numbers of mitochondria were counted manually. For normalization, the length of the neurites was measured using the Fiji plugin
Simple Neurite Tracer.

Live-Imaging Mitochondrial Trafficking
Transfected neurons were visualized with the Olympus FV3000
confocal laser scanning microscope with a silicon-oil immersion
633 objective. A 1.63–2.03 digital zoom was used for better
viewing. Images were taken at 5-s intervals for a total of 100
frames.

Statistical Analysis
All data from at least three independent experiments are expressed
as means ± SEM. All replicates are from different batches of organoids that have been dissociated in separate experiments. GraphPad
Prism 8 was used for statistical analysis. The normality of data was
assessed using the Shapiro-Wilk test and variances were compared
using the Brown-Forsythe test. Data were analyzed with the
unpaired, two-tailed Student’s t test and one- or two-way ANOVA
followed by Tukey-Kramer multiple-comparisons test, as indicated
in the figure legends. Differences were considered significant when
p < 0.05.
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Figure S1
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Supplementary Figure 1. Generation of footprint-free iPSC clones with episomal vectors. Related to
Figure 1.
(A) PCR analysis evaluating the removal of episomal vectors from the iPSC clones (P=passage number).
Arrowheads indicate the bands for OriP (upper) from the episomal vector, and endogenous OCT4
(lower). 9 out of 11 clones and 5 out of 16 clones were free of episomal vectors for patient #1 and #2,
respectively.
(B) G-banding karyotype analysis of representative iPSC clones.
(C) DNA sequence of iPSC clone confirming the excision of the selection cassette without any unintended
mutations. The data representatively shows an iPSC clone derived from patient #1 (RW#1-9)
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Supplementary Figure 2. Phosphorylation analysis of R406W mutant tau. Related to Figure 3.
(A-B) Western blot analysis investigating tau phosphorylation level at T181 (A). pT181 levels were
significantly reduced in the R406W mutant samples derived from patient #3 relative to total tau (K9JA) (B)
(n=3 independent experiments; one-way ANOVA followed by Tukey`s test).
(C-D) Western blot analysis investigating tau phosphorylation level at S404 (C). pS404 level was
significantly reduced in the R406W mutant samples relative to total tau (K9JA) (D) (n=3 independent
experiments; one-way ANOVA followed by Tukey`s test).
(E-F) Western blot analysis of Patient #3 iPSC-derived neurons with pan-tau antibody Tau5 (E) revealed
an increase in the ratio of 48kD tau (lower band; arrowhead) to total tau (both 48kD and 55kD bands) (F)
(n=3 independent experiments; Student`s t-test).
(G) Representative western blot analysis with total tau antibody Tau5 with or without dephosphorylating
the samples with λ-phosphatase. The downwards shift of the 48kD and 55kD bands after dephosphorylation
indicates that both bands represent phosphorylated forms of tau with different degrees of phosphorylation.
Error bars indicate mean±SEM; *p<0.05, **p<0.01, ***p<0.001.
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Supplementary Figure 3. Effect of kinases on the phosphorylation of R406W mutant tau. Related to
Figure 3.
(A) Western blot analysis of the C-terminus fragment of WT and R406W (RW) tau after incubation with
each respective kinase. In WT tau, S404 was directly phosphorylated by GSK3β and Cdk5, whereas S409
was directly phosphorylated by PKA and Rho-kinase (RhoK), both of which were impaired by the R406W
mutation. GSK3β weakly phosphorylated WT and RW tau at S409 to a similar extent.
(B-C) Western blot analysis investigating the dose-dependent effects of GSK3β inhibitor CHIR99021 on
the phosphorylation pattern of tau in WT (201B7) iPSC-derived neurons (B). Quantification of the ratio of
48kD tau to total tau (both 48kD and 55kD bands) revealed a dose-dependent increase of the ratio with
CHIR99021 treatment (C) (n=3 independent experiments; one-way ANOVA followed by Tukey`s test).
(D-F) Western blot analysis of WT and R406W (RW) mutant tau conjugated with GFP and co-expressed
with the respective kinases in COS-7 cells with tau antibodies detecting phosphorylation at S404 or S409
(D) and quantification of the phosphorylation levels (S404, E; S409, F). All of the kinases enhanced
phosphorylation at S404 in WT tau, but no basal phosphorylation at S404 could be detected in RW tau, and
none of the kinases were able to enhance the phosphorylation level (E). Co-expression of PKA or Rhokinase enhanced the phosphorylation of WT tau at S409, but not with RW tau (F) (n=3 independent
experiments; Student`s t-test).
(G-H) Western blot analysis of β-Catenin and p-β-Catenin (S33/S37/T41) levels in the iPSC-derived
neurons (G). p-β-Catenin levels did not differ significantly among neuronal lines (H) (n=3 independent
experiments).
(I) Measurement of phosphatase activity in the iPSC-derived neurons. The amount of phosphate released
did not differ among neuronal lines, indicating that there was no significant difference in phosphatase
activity (n=3 independent experiments).
Error bars indicate mean±SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Supplementary Figure 4. Tau fragmentation analysis in iPSC-derived neurons. Related to Figure 4.
(A-D) Western blot analysis of iPSC-derived neurons with total tau antibodies Tau5 (A) and Tau46 (C)
revealed an increase in the ratio of tau fragments (bracket) to full-length tau (brace; tau5, B; tau46, D)
(n=3~4 independent experiments, mean±SEM; *p<0.05, **p<0.01; One-way ANOVA followed by Tukey`s
test).
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Supplementary Figure 5. Phenotype analysis of iPSC-derived neurons at earlier timepoints. Related
to Figure 3, 4, 5.
(A-C) Western blot analysis investigating tau phosphorylation levels at T181 and S404 (A) in iPSC-derived
neurons 10 days post dissociation. Phosphorylation levels at both epitopes were significantly reduced in the
R406W mutant samples at this timepoint (T181, B; S404, C) relative to total tau (K9JA) (n=3 independent
experiments).
(D-E) Western blot analysis with total tau antibody Tau5 (D) revealed an increase in the ratio of 48kD tau
(arrowhead) to total tau (both 48kD and 55kD bands) in the R406W mutant samples (E) in iPSC-derived
neurons 10 days after dissociation (n=3 independent experiments).
(F) Quantification of the percentage of tau on axons or dendrites of the neurons. The percentage of tau in
either of the compartments did not significantly differ among neuronal lines (n=3 independent experiments).
(G) Quantification of the number of axonal puncta per neurite length (μm). The number of axonal puncta
did not significantly differ among neuronal lines (n=3 independent experiments).
Error bars indicate mean±SEM. One-way ANOVA followed by Tukey`s test was performed; *p<0.05,
**p<0.01, ***p<0.001.

Table S1. iPSC donor information Related to Figure 1.
Patient #1*

Patient #2*

Patient #3

Gender

Female

Male

Female

Age at onset

50

47

N/A

Age at examination

67

48

N/A

Age at biopsy

N/A

N/A

70

Origin

Peripheral

Peripheral

Fibroblast

mononuclear
blood cell

mononuclear
blood cell

Reprogramming
method

Episomal

Episomal

Sendai virus

Gene-editing

WT, homo

WT, homo

WT

N/A=not available, WT=wild-type, homo=homozygous
*Modified from Ikeuchi et al., 2011

Supplemental Experimental Procedures

Generation of iPSCs from the patient blood cells
iPSCs were generated from peripheral blood mononuclear cells (PBMCs) or T cells as previously
described (Okita et al., 2013, Ichiyanagi et al., 2016, Nakamoto et al., 2018). Briefly, PBMCs were isolated
by centrifuging at 15000 g for 20 minutes at room temperature, using the BD VACUTAINER CPT (BD,
Franklin Lakes, NJ, USA). Remaining PBMCs were maintained in T cell medium and cultured as T cells.
Episomal vectors pCE-hOCT3/4, pCE-hSK, pCE-hUL, pCE-mP53DD (all 0.63 µg), which express
OCT3/4, SOX2 and KLF4, L-MYC and LIN28, and p53 dominant negative mutant, respectively, as well
as pCXB-EBNA1 (0.5 µg), which express EBNA1 (AddGene IDs: 41813, 41814, 41855, 41856, 41857)
were electroporated into 3 × 106 PBMCs or T cells using a Nucleofector 2b Device (Lonza, Basel,
Switzerland, V-024 program) with an Amaxa Human T-cell Nucleofector kit (Lonza) according to the
manufacturer's instructions. 2 days after transfection, an equal volume of iPSC medium was added to the
culture without aspirating the T cell medium. The medium was completely replaced with iPSC medium 4
days after transfection. Colonies with a human embryonic stem cell (ESC)-like morphology were picked
up between 26~33 days after transfection and cultured further for cultivation and evaluation. All
experimental procedures for iPSCs derived from patients were approved by the Keio University School
of Medicine Ethics Committee (approval no. 20080016).

Generation of cerebral organoids
Organoids were generated from the iPSCs as previously described with slight modifications (Figure 2A;
Lancaster et al., 2013; Kadoshima et al., 2013). Briefly, on day 0 of organoid culture, iPSCs were
dissociated and 3 × 104 cells were aggregated into embryoid bodies (EBs) in low attachment V-shaped 96well plates (Sumitomo Bakelite, Tokyo, Japan). For 6 days, the EBs were maintained in StemFit AK02N
medium supplemented with 30 μM Y-27632, as well as 5 µM SB431542 and 2.5 μM IWP-2 to specifically
induce them into the forebrain region of neural tissue. On day 6, the medium was changed to neural
induction medium consisting of 1% (v/v) N2 Supplement (Thermo Fisher Scientific), 1% (v/v) Glutamax
(Thermo Fisher Scientific), 1% (v/v) MEM-NEAA, 2.5 μM IWP-2, 5 µg/ml sodium heparan sulfate
(Sigma-Aldrich), and 1% (v/v) penicillin/streptomycin in DMEM/Ham`s F-12 medium (Thermo Fisher
Scientific). On day 9, the EBs were transferred into Ultra-Low Attachment surface 6 well plates (Corning,
Corning, NY, USA), grown in differentiation media composed of a 1:1 mixture of DMEM/Ham`s F-12
medium and Neurobasal medium (Thermo Fisher Scientific), supplied with 1% (v/v) N2 supplement, 2%
(v/v) B27 supplement without vitamin A (Thermo Fisher Scientific), 100 µM 2-mercaptoethanol, 2.5 µg/ml
insulin (Wako), 1% (v/v) Glutamax, 0.5% (v/v) MEM-NEAA, and 1% (v/v) Matrigel (Corning). The plates
containing the EBs were maintained on a shaker to enhance nutrient and oxygen absorption. On day 15, the
medium was changed to differentiation medium consisting of B27 supplement with vitamin A (Thermo

Fisher Scientific). The medium was changed every 5~7 days from then on.

Pluripotency check of iPSC clones
The iPSC clones were immunostained for pluripotency markers alkaline phosphatase using
SIGMAFAST BCIP/NBT (Sigma-Aldrich) according to the manufacturer’s instructions, and anti-TRA-160 (mouse, 1:500 dilution, EMD Millipore, Billerica, MA, USA).

Karyotype analysis
G-banding analysis of the iPSC lines was conducted by the LSI Medience Corporation (Tokyo, Japan).

Construction of targeting vectors and Cas9 vector
The MAPT locus containing exon 13 with or without the R406W mutation was cloned from the patient
genome into the pCR-Blunt II-TOPO vector (Thermo Fisher Scientific) by PCR using the following
primers: forward TTTTTGGCTTTACCAGATGCTCA, reverse TCATTACTGAGAAGGGGTGGTGA.
The PCR conditions are as follows: 35 cycles of 98℃ for 10s, followed by 68℃ for 3 min 30s. The
PrimeSTAR Max DNA Polymerase (Takara, Kusatsu, Japan) was used. A 2-kb 5´arm and 5-kb 3´arm
consisting of exon 13 with the mutation site were cloned individually into separate entry vectors by PCR
using

the

following

primers:

5´arm

AACTTTGTATAATAAAGTTGTGACTGAGTGGGTCTGGATAGG,

forward,

5´arm

reverse,

CAGACTATCTTTCTAGGGTTAAGTTTCTTGTGTACCCTCCAG,

3´arm

forward,

ATGATTATCTTTCTAGGGTTAAAATGATCACTGTCTCTGGGG,

3´arm

reverse,

CAACTTTGTATAGAAAAGTTGCTAAGGGTGCGTGGGAAAGA. The PCR conditions are as follows:
98℃ for 1 min, followed by 20 cycles of 98℃ for 10s and 68℃ for 2 min (5´arm) or 5 min (3´arm). Using
the GeneArt Seamless Cloning and Assembly Kit (Thermo Fisher Scientific), these entry vectors, along
with another entry vector consisting of a selection cassette with Puromycin-ΔTK driven by a mouse PGK
promoter and PiggyBac inverse terminal repeats (ITRs) at both ends (Figure 2A), were assembled into a
single destination vector.
The Cas9 expression plasmid vector pSPCas9(BB)-2A-Puro (PX459) was obtained from AddGene (ID:
48139). Complementary oligonucleotides encoding sgRNA were annealed and cloned into the BbsI site in
the

Cas9

vector.

The

sequences

of

the

oligonucleotides

are

as

follows:

upper,

CTTAAAATGATCACTGTCTCTGG, lower, AAACGAGACAGTGATCATTTTAAGC.

Transfection of targeting vector into iPSCs
Feeder-free iPSCs were pre-treated with 10 µM Y-27632 (EMD Millipore) overnight to prevent apoptosis
induced by dissociation (Watanabe et al., 2007). The iPSCs were dissociated into single cells with Tryple
Select (Thermo Fisher Scientific). The targeting vector with or without the R406W mutation and the Cas9

expression vector were electroporated into 1 × 106 iPSCs using NEPA21 (NepaGene, Chiba, Japan).
Transfected cells were plated onto iMatrix-511-coated 60 mm dishes (Iwaki, Chiba, Japan). Y-27632 was
removed from the culture 2 days after the transfection. Cells were treated with 0.75~0.8 µg/µl puromycin
on days 2, 3, 6, and 8 after plating.
Colonies with a human ESC-like morphology were picked up and DNA from each colony was extracted
using the DNeasy Blood & Tissue Kit (QIAGEN, Hilden, Germany). PCR analysis evaluating the knockin

of

targeting

vectors

was

performed

using

the

following

primers:

forward,

GCGTCCCAGAAAGGGTATAGG, reverse GTCACGTAAAAGAATTGTTTGTTGA. The DNA of the
clones in which knock-in occurred was analyzed by Sanger sequencing with the 3130xl Genetic Analyzer
(Applied Biosystems, Waltham, MA, USA) to check the mutation site.

Excision of PiggyBac cassette from iPSCs
Feeder-free iPSCs pre-treated with 10 µM Y-27632 overnight were dissociated into single cells with
Tryple Select (Thermo Fisher Scientifc). 1 µg PBx (Excision Only PiggyBac Transposase; Funakoshi,
Tokyo, Japan) was transfected into 1 × 106 iPSCs with the GeneJuice Transfection Reagent (EMD
Millipore) and plated onto iMatrix-511-coated 10 cm dishes (Iwaki). DNA extraction and PCR analysis
were performed as described above.

Generation of cerebral organoids
Organoids were generated from the iPSCs as previously described with slight modifications (Figure 2A;
Lancaster et al., 2013; Kadoshima et al., 2013). Briefly, on day 0 of organoid culture, iPSCs were
dissociated and 3 × 105 cells were aggregated into embryoid bodies (EBs) in low attachment V-shaped 96well plates (Sumitomo Bakelite, Tokyo, Japan). For 6 days, the EBs were maintained in StemFit AK02N
medium supplemented with 30 μM Y-27632, as well as 5 µM SB431542 and 2.5 μM IWP-2 to specifically
induce them into the forebrain region of neural tissue. On day 6, the medium was changed to neural
induction medium consisting of 1% (v/v) N2 Supplement (Thermo Fisher Scientific), 1% (v/v) Glutamax
(Thermo Fisher Scientific), 1% (v/v) MEM-NEAA, 2.5 μM IWP-2, 5 µg/ml sodium heparan sulfate
(Sigma-Aldrich), and 1% (v/v) penicillin/streptomycin in DMEM/Ham`s F-12 medium (Thermo Fisher
Scientific). On day 9, the EBs were transferred into Ultra-Low Attachment surface 6 well plates (Corning,
Corning, NY, USA), grown in differentiation media composed of a 1:1 mixture of DMEM/Ham`s F-12
medium and Neurobasal medium (Thermo Fisher Scientific), supplied with 1% (v/v) N2 supplement, 2%
(v/v) B27 supplement without vitamin A (Thermo Fisher Scientific), 100 µM 2-mercaptoethanol, 2.5 µg/ml
insulin (Wako), 1% (v/v) Glutamax, 0.5% (v/v) MEM-NEAA, and 1% (v/v) Matrigel (Corning). The plates
containing the EBs were maintained on a shaker to enhance nutrient and oxygen absorption. On day 15, the
medium was changed to differentiation medium consisting of B27 supplement with vitamin A (Thermo
Fisher Scientific). The medium was changed every 5~7 days from then on.

Phosphorylation analysis of tau
Human Tau cDNAs (0N3R, WT and R406W) were synthesized, and subcloned into pEGFP-c1
mammalian

expression

vector.

The

C-terminus

of

Tau

(308-351

aa;

VVSGDTSP(R/W)HLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL) was subcloned into pGEX2T E. coli expression vector. GST-PKACa (#01-127) and GST-GSK3β (#04-141) were purchased from
Carna Biosciences (Kobe, Japan). GST-Rho-kinase-cat, GST-CDK5, and GST-p35 were expressed in Sf9
cells using a baculovirus system and purified using glutathione Sepharose beads (Amano et al., 1999).
For in vitro analysis, GST-Tau-C (1 μM) was incubated with each kinase (30 nM) in a reaction mixture
(25 mM Tris-HCl at pH 7.5, 1 mM EDTA, 1 mM DTT, 5 mM MgCl2, and 50 μM ATP) for 30 min at 30°C.
The reaction mixtures were boiled in SDS sample buffer and subjected to western blot analysis.
Plasmids encoding Tau and each kinase were transfected into COS7 cells using the Lipofectamine® 2000
reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol. The cells were lysed with SDS
sample buffer and subjected to western blot analyses.

Immunofluorescence antibodies
The following primary antibodies and dilutions were used: anti-TBR1 (rabbit, Abcam, Cambridge, UK,
ab31940, 1:200 dilution), anti-MAP2 (chicken, Abcam ab5392, 1:10000 dilution), anti-βIII-tubulin (rabbit,
Abcam, ab18207, 1:1000 dilution), anti-FOXG1 (rabbit, Abcam, ab18259, 1:500), and anti-tau (RTM38,
Fujifilm Wako Pure Chemical, Osaka, Japan; rat, 1:5000 dilution). The following day, the cells were
incubated with secondary antibodies for 1 hour at room temperature. Secondary antibodies used include
Goat Alexa 488, 555, and 647 conjugates (Thermo Fisher Scientific, 1:500 dilution). Nuclear staining was
performed with the Cellstain DAPI solution (DOJINDO, Kumamoto, Japan, 1:1000 dilution) for 15~20
minutes at room temperature.

Western blot antibodies and reagents
The following primary antibodies were used: anti-tau (K9JA) (Agilent Technologies, Santa Clara, CA,
USA, 1:10000 dilution), Tau5 (mouse, 1:2000 dilution), Tau12 (mouse, 1:10000 dilution), Tau46 (mouse,
Cell Signaling Technology, Beverly, MA, USA, 4019, 1:2000 dilution), anti-Tau-pT181 (rat, Cell
Engineering Corporation, Osaka, Japan, 1:1000 dilution), anti-Tau-pS409 (rabbit, 1:1000 dilution; Amano
et al., 2003), anti-β-Catenin (rabbit, Cell Signaling Technology, 8480, 1:2000 dilution), anti-p-β-Catenin
(S33/S37/T41) (rabbit, Cell Signaling Technology, 9561, 1:1000 dilution), and anti-GAPDH (rabbit,
Sigma-Aldrich, G9545, 1:10000 dilution).
For protease inhibition, dissociated neurons were pre-treated with either 120 µM Z-VAD-FMK (Peptide
Institute, Osaka, Japan), pan-caspase inhibitor, or 250 µM ALLN (Nacalai Tesque), pan-calpain inhibitor,
for 24 hours before cell lysis.

For kinase inhibition, dissociated neurons were pretreated with 1 µM KT5720 (Tocris), 10 µM Y27632
(Merck), 20 µM SB216763 (Tocris), 20 µM Roscovitine (Sigma), or CHIR99021 (0.1 µM, 1 µM, or 10
µM) for 24 hours before cell lysis.

Phosphatase activity assay
Phosphatase activity was measured using the Serine/Threonine Phosphatase Assay System (Promega,
Madison, WI, USA) according to the manufacturer’s instructions. Briefly, cells were lysed in phosphatase
storage buffer, which consisted of 0.05M Tris-HCl (pH7.0), 0.1mM EGTA, 0.1% 2-ME, 0.4 mM Pefabloc
(AEBSF), and 10 µg/ml leupeptin and endogenous phosphate was removed as using the spin columns
provided in the assay kit. To measure PP2A activity, the reaction premix, which consists of 5x PP2A reaction
buffer (250 mM imidazole (pH7.2), 1mM EGTA, 0.1% 2-ME, 0.5mg/ml BSA, 0.4 mM Pefabloc (AEBSF),
and 10 µg/ml leupeptin), synthetic phosphopeptide, and the lysate samples, was prepared in duplicate in 96
well plates and allowed to react for 10 min at 37℃. Reaction was stopped with the addition of Molybdate
Dye/Additive mixture and the dye color was allowed to develop for 15~30 min at room temperature.
Absorbance was measured at 600 nm with the Glomax Microplate Reader (Promega) to assess the amount
of phosphate released.

List of plasmids used in this study
Plasmid name

Features

pSPCas9(BB)-2A-Puro

Mammalian expression vector, CBh promoter, Cas9

(PX459)
pGEX-2T-Tau-C-WT/R406W

E.coli expression vector, tac promoter, GST-Tau-C (human 0N3R, 308351 aa)

pEGFP-c1-Tau-WT/R406W

Mammalian expression vector, CMV promoter, EGFP-Tau (human
0N3R, 1-351 aa)

pCGN-HA-GSK3B-CA

Mammalian expression vector, CMV promoter, HA-GSK3B-CA
(human)

pEF-BOS-GST-PKA-CA

Mammalian expression vector, EF-1α promoter, GST-PKA-CA
(mouse)

pEF-BOS-GST-Rho-kinase-

Mammalian expression vector, EF-1α promoter, GST-Rho-kinase

cat

catalytic region (bovine)

pEF-BOS-GST-CDK5

Mammalian expression vector, EF-1α promoter, GST-CDK5 (human)

pEF-BOS-GST-p35

Mammalian expression vector, EF-1α promoter, GST-p35 (human)

pcDNA3-Mito-eYFP

Mammalian expression vector, CMV promoter, Mito-eYFP

ptdTomato

Mammalian expression vector, CMV promoter, tdTomato
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